Nymox Pharmaceutical Corporation (NYMX)

Oncology Corporate Profile

Stock Performance

3.9800
-0.0400

HQ Location

9900 Cavendish Boulevard
St. Laurent
Quebec, Canada H4M 2V2

Company Description

Nymox Pharmaceutical Corporation is engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company's new drug for benign prostatic hyperplasia (BPH) is in Phase 3 development in the U.S. and Europe. The Company's candidate drug for prostate cancer is currently in Phase 2 testing in the U.S.

Website: http://www.nymox.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
NX-1207pro-apoptotic focal therapyProstate cancerII

View additional information on product candidates here »

Source: http://www.nymox.com

Recent News Headlines

7/25/2017 12:29 am

7/25/2017 12:29 am

7/25/2017 12:29 am

7/25/2017 12:29 am

7/4/2017 12:19 pm

7/4/2017 12:19 pm

7/4/2017 12:19 pm

5/31/2017 06:19 am

5/31/2017 06:19 am

5/24/2017 06:18 am

5/24/2017 06:18 am

5/24/2017 06:18 am

5/16/2017 12:18 am

5/16/2017 12:18 am

5/8/2017 06:18 am

5/3/2017 06:18 am

Pacific Biosciences of California and Nymox Pharmaceutical Move Up On Bullish Product Environments

3/30/2017 01:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Both companies had active trading sessions on Wednesday, as news of insider buying and optimistic product forecasts drew attention to the two biotech stocks. ...

Nymox Provides Update on Fexapotide Development

3/29/2017 02:04 pm

[GlobeNewswire] - HASBROUCK HEIGHTS, N.J., March 29, 2017-- Nymox Pharmaceutical Corporation provided an update today on the Company's development activities for Fexapotide Triflutate, its new drug for prostate enlargement. ...

Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy

11/29/2016 02:04 pm

[GlobeNewswire] - HASBROUCK HEIGHTS, N.J., Nov. 29, 2016-- Nymox Pharmaceutical Corporation is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received ...

Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment

10/11/2016 02:00 pm

[GlobeNewswire] - HASBROUCK HEIGHTS, N.J., Oct. 11, 2016-- Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for ...

Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery

8/29/2016 03:02 pm

[at noodls] - NEWS RELEASE Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com For Immediate Release: HASBROUCK HEIGHTS, NJ (August 24, 2016) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) ...

Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

8/29/2016 03:02 pm

[at noodls] - NEWS RELEASE Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com For Immediate Release: Dramatic Decrease in Prostate Cancer and Major Reduction in Need For BPH Prostate Surgery ...